LOS ANGELES -- (Business Wire)

Lundin Law PC announces it is investigating claims against Clovis Oncology, Inc. (“Clovis” or the “Company”) (NASDAQ: CLVS) concerning possible violations of federal securities laws. The investigation is related to allegations that certain statements issued by Clovis were false and misleading concerning the Company’s financial performance.

To participate in this class action lawsuit, please contact Brian Lundin, Esquire, of Lundin Law PC, at 888-713-1033, or via e-mail at brian@lundinlawpc.com.

No class has been certified in the above action. Until a class is certified, you are not considered represented by an attorney. You may also choose to do nothing and be an absent class member.

The investigation concerns whether the Company violated Sections 10(b) and 20(a) of the Securities Exchange Act of 1934. Specifically, the investigation will focus on the Company’s November 16, 2015, announcement that potential approval of its lung cancer treatment rociletinib will likely be delayed.

Lundin Law PC was created by Brian Lundin, a securities litigator based in Los Angeles.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.

View source version on businesswire.com: http://www.businesswire.com/news/home/20151201006941/en/

Contacts:

Lundin Law PC
Brian Lundin, Esq.
Telephone: 888-713-1033
Facsimile: 888-713-1125
brian@lundinlaw.com

Source: Lundin Law PC